Medtronic plc Files 8-K on Shareholder Votes and Debt
Ticker: MDT · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1613103
| Field | Detail |
|---|---|
| Company | Medtronic PLC (MDT) |
| Form Type | 8-K |
| Filed Date | Oct 21, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, corporate-governance
TL;DR
Medtronic filed an 8-K detailing shareholder votes and various senior notes due between 2025 and 2031.
AI Summary
On October 17, 2024, Medtronic plc filed an 8-K to report the submission of matters to a vote of security holders and financial statements. The filing also details various senior notes due in the coming years, including notes due 2025, 2027, 2028, 2029, and 2031, with varying interest rates.
Why It Matters
This filing provides transparency regarding Medtronic's corporate governance actions and its outstanding debt obligations, which are key factors for investors assessing financial health and management.
Risk Assessment
Risk Level: low — This is a routine filing reporting on shareholder votes and debt, not indicating any immediate operational or financial distress.
Key Numbers
- 2025 — Senior Notes Maturity Year (Represents upcoming debt obligations for Medtronic.)
- 2031 — Senior Notes Maturity Year (Represents the longest-dated senior notes mentioned in the filing.)
Key Players & Entities
- Medtronic plc (company) — Filer of the 8-K
- 2025 (date) — Maturity year for senior notes
- 2027 (date) — Maturity year for senior notes
- 2028 (date) — Maturity year for senior notes
- 2029 (date) — Maturity year for senior notes
- 2031 (date) — Maturity year for senior notes
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What are the interest rates on the senior notes due in 2025?
The filing lists senior notes due in 2025 with interest rates of 0.250%, 0.000%, and 2.625%.
What is the maturity date for the senior notes with a 3.650% interest rate?
The senior notes with a 3.650% interest rate are due in 2029.
Does the filing mention any new debt issuance?
The filing primarily lists existing senior notes with various maturity dates and interest rates, and does not explicitly mention new debt issuance in the provided excerpt.
What is the filing date of this 8-K?
This 8-K was filed on October 21, 2024.
Filing Stats: 1,089 words · 4 min read · ~4 pages · Grade level 9.6 · Accepted 2024-10-21 16:21:45
Key Financial Figures
- $0.0001 — registered Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange
Filing Documents
- mdt-20241017.htm (8-K) — 98KB
- 0001613103-24-000151.txt ( ) — 388KB
- mdt-20241017.xsd (EX-101.SCH) — 7KB
- mdt-20241017_def.xml (EX-101.DEF) — 25KB
- mdt-20241017_lab.xml (EX-101.LAB) — 51KB
- mdt-20241017_pre.xml (EX-101.PRE) — 27KB
- mdt-20241017_htm.xml (XML) — 18KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On October 17, 2024, the Company held its 2024 Annual General Meeting of Shareholders in order to: (1) elect, by separate resolutions, ten directors, each to hold office until the 2025 Annual General Meeting of the Company and until his or her successor is elected; (2) ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2025 and authorize, in a binding vote, the Company's Board of Directors, acting through the Audit Committee, to set the auditor's remuneration; (3) approve, in a non-binding advisory vote, named executive officer compensation; (4) renew the Board's authority to issue shares; (5) renew the Board's authority to opt out of pre-emption rights; and (6) authorize the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. At the close of business on August 23, 2024, the record date of the Annual General Meeting, 1,282,467,348 Company ordinary shares were outstanding and entitled to vote. The holders of a total of 1,118,364,589 ordinary shares were present at the Annual General Meeting, either in person or by proxy, which total was not less than a majority of the issued and outstanding ordinary shares entitled to vote and thus constituted a quorum. The final voting results and the votes used to determine the results for each proposal are set forth below: 1. The shareholders elected each of the ten nominees to the Board of Directors, to hold office until the 2025 Annual General Meeting of the Company and until his or her successor is elected, as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE Craig Arnold 952,980,300 45,113,878 1,927,552 118,342,859 Scott C. Donnelly 964,223,711 34,734,436 1,063,583 118,342,859 Lidia L. Fonseca 983,895,789 15,081,990 1,043,951 118,342,859 Andrea J. Goldsmith, Ph.D. 994,796,259 4,135,950 1,089,521 118,342,
01. Exhibits
Item 9.01. Exhibits. (d) List of Exhibit Exhibit Number Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Medtronic plc By /s/ Ivan K. Fong Date: October 21, 2024 Ivan K. Fong Executive Vice President, General Counsel and Secretary EXHIBIT INDEX Exhibit Number Description 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).